Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), BioNexus Gene Lab's 3-1 Month Momentum % is -20.10%.
The industry rank for BioNexus Gene Lab's 3-1 Month Momentum % or its related term are showing as below:
BGLC's 3-1 Month Momentum % is ranked worse than 74.8% of 1627
companies
in the Chemicals industry
Industry Median: -6.95
vs BGLC: -20.10
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioNexus Gene Lab 3-1 Month Momentum % Related Terms
BGLC vs VYST, QGAI, CNEY: 3-1 Month Momentum % Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab 3-1 Month Momentum % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a 3-1 Month Momentum % of -20.10% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #1217 out of 1627 companies in the Chemicals industry, placing it in the top 74.8%.
Is BioNexus Gene Lab's 3-1 Month Momentum % too high?
BioNexus Gene Lab's current 3-1 Month Momentum % is -20.10%. Based on the distribution chart, BioNexus Gene Lab ranks #1217 out of 1627 companies in the Chemicals industry, which is below the industry midpoint. Overall, BioNexus Gene Lab has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's 3-1 Month Momentum % compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1217 out of 1627 companies for 3-1 Month Momentum %. This places BioNexus Gene Lab in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Chemicals company?
A good 3-1 Month Momentum % depends on the Chemicals industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current 3-1 Month Momentum % is -20.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.59 — trading 26.9% above its estimated fair value. The current 3-1 Month Momentum % is -20.10%. BioNexus Gene Lab's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current 3-1 Month Momentum % is -20.10% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.59 is trading 26.9% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
3-1 Month Momentum %: -20.10%
GF Value™: $1.25 vs. price of $1.59 (26.9% above fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
55GF Score
Get the complete analysis for BGLC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
